Compare DexCom, Inc. (DXCM) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs LyondellBasell Industries NV — how do they compare? DexCom, Inc. trades at $77.81 (market cap $28.06B), while LyondellBasell Industries NV trades at $58.85 (market cap $18.72B). The key difference: DexCom, Inc. is the larger of the two by market cap, and LyondellBasell Industries NV pays a 7.1% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | LYB | |
|---|---|---|
Market Cap | $28.06B | $18.72B |
Sector | Health | Basic Materials |
52-Week High | $89.53 | $82.38 |
52-Week Low | $54.84 | $42.28 |
Enterprise Value | $27.03B | $30.34B |
Dividend Yield | — | 7.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
LyondellBasell (LYB) trades at $58.56, up 0.4% on the day, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating estimates in Q3 2025 and Q1 2026 but missing in Q4 2025. Recent news highlights strategic partnerships for sustainable packaging, including a collaboration with Mondelez announced in July 2026. However, fundamental challenges persist with a net loss of $745 million in 2025 and negative profit margins.
The outlook presents a dichotomy: analyst consensus is a 'Buy' with a $73.11 price target, and recent Zacks upgrades to 'Strong Buy' in June 2026 reflect optimism on earnings prospects. Key opportunities include cost-cutting initiatives and a pivot to higher-margin polymers. Primary risks are sustained revenue decline, elevated debt, and cyclical industry pressures that could delay a profitability turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
